Giovanni Blandino

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5731538/publications.pdf

Version: 2024-02-01

212 papers	12,849 citations	23567 58 h-index	28297 105 g-index
215 all docs	215 docs citations	215 times ranked	16266 citing authors

#	Article	IF	Citations
1	Interaction of c-Abl and p73Î± and their collaboration to induce apoptosis. Nature, 1999, 399, 809-813.	27.8	529
2	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene, 1999, 18, 477-485.	5.9	411
3	The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature, 2002, 419, 853-857.	27.8	390
4	Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell, 2006, 10, 191-202.	16.8	386
5	Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity. Journal of Biological Chemistry, 2001, 276, 15164-15173.	3.4	368
6	The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. Molecular Cell, 2005, 18, 447-459.	9.7	318
7	The circ<scp>RNA</scp>â€“micro<scp>RNA</scp> code: emerging implications for cancer diagnosis and treatment. Molecular Oncology, 2019, 13, 669-680.	4.6	300
8	DNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes. Molecular Cell, 2002, 9, 175-186.	9.7	298
9	The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell, 2018, 33, 244-258.e10.	16.8	270
10	Rescue of Hippo coactivator YAP1 triggers DNA damageâ€“induced apoptosis in hematological cancers. Nature Medicine, 2014, 20, 599-606.	30.7	250
11	Mutant p53: an oncogenic transcription factor. Oncogene, 2007, 26, 2212-2219.	5.9	241
12	Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53. Cancer Cell, 2010, 17, 273-285.	16.8	228
13	PML, YAP, and p73 Are Components of a Proapoptotic Autoregulatory Feedback Loop. Molecular Cell, 2008, 32, 803-814.	9.7	224
14	Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73. Journal of Biological Chemistry, 2000, 275, 29503-29512.	3.4	217
15	Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities. Journal of Biological Chemistry, 2002, 277, 18817-18826.	3.4	203
16	Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nature Communications, 2012, 3, 865.	12.8	198
17	CircRNAs: role in human diseases and potential use as biomarkers. Cell Death and Disease, 2021, 12, 468.	6.3	191
18	The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nature Structural and Molecular Biology, 2009, 16, 1086-1093.	8.2	182

#	Article	IF	Citations
19	The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. Genome Biology, 2017, 18, 237.	8.8	179
20	Mutant p53 Enhances Nuclear Factor ÎºB Activation by Tumor Necrosis Factor Î± in Cancer Cells. Cancer Research, 2007, 67, 2396-2401.	0.9	178
21	Pin1 Links the Activities of c-Abl and p300 in Regulating p73 Function. Molecular Cell, 2004, 14, 625-636.	9.7	165
22	miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death and Disease, 2012, 3, e423-e423.	6.3	160
23	New therapeutic strategies to treat human cancers expressing mutant p53 proteins. Journal of Experimental and Clinical Cancer Research, 2018, 37, 30.	8.6	160
24	<scp>YAP</scp> enhances the proâ€proliferative transcriptional activity of mutant p53 proteins. EMBO Reports, 2016, 17, 188-201.	4.5	154
25	Oral mucositis: the hidden side of cancer therapy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 210.	8.6	146
26	Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13710-13715.	7.1	141
27	MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death and Differentiation, 2012, 19, 1038-1048.	11.2	136
28	Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene, 1999, 18, 2643-2649.	5.9	126
29	Identification of Direct p73 Target Genes Combining DNA Microarray and Chromatin Immunoprecipitation Analyses. Journal of Biological Chemistry, 2002, 277, 43359-43368.	3.4	125
30	The Transcriptional Repressor ZEB Regulates p73 Expression at the Crossroad between Proliferation and Differentiation. Molecular and Cellular Biology, 2001, 21, 8461-8470.	2.3	117
31	Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Molecular Oncology, 2016, 10, 1008-1029.	4.6	115
32	Oncogenic MicroRNAs: Key Players in Malignant Transformation. Cancers, 2015, 7, 2466-2485.	3.7	114
33	miR-155 Drives Telomere Fragility in Human Breast Cancer by Targeting TRF1. Cancer Research, 2014, 74, 4145-4156.	0.9	108
34	Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 89-100.	4.1	107
35	Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene, 1997, 15, 2717-2725.	5.9	102
36	EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors. Science Signaling, 2010, 3, ra43.	3.6	100

#	Article	IF	Citations
37	YAP: At the crossroad between transformation and tumor suppression. Cell Cycle, 2009, 8, 49-57.	2.6	99
38	Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene, 1998, 17, 1923-1930.	5.9	98
39	Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 627-635.	2.5	91
40	YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. Cancers, 2018, 10, 137.	3.7	89
41	Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle, 2010, 9, 2950-2959.	2.6	86
42	miRâ€10b*, a master inhibitor of the cell cycle, is downâ€regulated in human breast tumours. EMBO Molecular Medicine, 2012, 4, 1214-1229.	6.9	85
43	Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73. Journal of Cell Biology, 2006, 172, 589-604.	5.2	84
44	The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle, 2008, 7, 3440-3447.	2.6	83
45	MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate Cancer. Cancer Discovery, 2012, 2, 236-247.	9.4	82
46	Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle, 2008, 7, 1870-1879.	2.6	81
47	From p63 to p53 across p73. FEBS Letters, 2001, 490, 163-170.	2.8	79
48	Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. Biochemical Journal, 2015, 469, 177-187.	3.7	79
49	Reversible Dysfunction of Wild-Type p53 following Homeodomain-Interacting Protein Kinase-2 Knockdown. Cancer Research, 2008, 68, 3707-3714.	0.9	78
50	Prospective study on the role of glucose metabolism in breast cancer occurrence. International Journal of Cancer, 2012, 130, 921-929.	5.1	78
51	The mutant p53â€D4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO Reports, 2017, 18, 1331-1351.	4.5	78
52	Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53. Cancer Research, 2009, 69, 4818-4826.	0.9	76
53	Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget, 2015, 6, 35183-35201.	1.8	75
54	Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle, 2011, 10, 4330-4340.	2.6	74

#	Article	IF	Citations
55	Cheâ€1â€induced inhibition of <scp>mTOR</scp> pathway enables stressâ€induced autophagy. EMBO Journal, 2015, 34, 1214-1230.	7.8	66
56	A STAT3-NFkB/DDIT3/CEBPÎ² axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. Oncotarget, 2015, 6, 12637-12653.	1.8	65
57	Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma. Theranostics, 2018, 8, 1850-1868.	10.0	65
58	HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. Oncogene, 2004, 23, 5185-5192.	5.9	60
59	Oncogenic Intra-p53 Family Member Interactions in Human Cancers. Frontiers in Oncology, 2016, 6, 77.	2.8	59
60	Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Cell Discovery, 2017, 3, 17022.	6.7	59
61	Tumor suppressor microRNAs: A novel nonâ€coding alliance against cancer. FEBS Letters, 2014, 588, 2639-2652.	2.8	58
62	EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Science Signaling, 2015, 8, ra29.	3.6	57
63	miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 141.	8.6	55
64	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. Journal of Molecular Medicine, 2012, 90, 667-679.	3.9	54
65	YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer. Cancer Letters, 2021, 500, 51-63.	7.2	54
66	p73 and p63: Why Do We Still Need Them?. Cell Cycle, 2004, 3, 884-892.	2.6	52
67	Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. Carcinogenesis, 2013, 34, 1051-1061.	2.8	52
68	MCM7and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. Carcinogenesis, 2017, 38, 64-75.	2.8	52
69	Chromatin Dynamics of Gene Activation and Repression in Response to Interferon Î± (IFNÎ±) Reveal New Roles for Phosphorylated and Unphosphorylated Forms of the Transcription Factor STAT2. Journal of Biological Chemistry, 2011, 286, 20217-20227.	3.4	51
70	Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle, 2010, 9, 2878-87.	2.6	51
71	miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget, 2016, 7, 4009-4023.	1.8	49
72	Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. Oncotarget, 2016, 7, 20532-20548.	1.8	49

#	Article	IF	Citations
73	Negative Regulation of Î²4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression. Cancer Research, 2009, 69, 5978-5986.	0.9	48
74	MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies. Clinical Colorectal Cancer, 2014, 13, 37-45.e4.	2.3	46
75	Expression of the Î²4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells. Blood, 2002, 100, 96-106.	1.4	45
76	Mutant p53 proteins: Between loss and gain of function. Head and Neck, 2007, 29, 488-496.	2.0	45
77	Che-1 Promotes Tumor Cell Survival by Sustaining Mutant p53 Transcription and Inhibiting DNA Damage Response Activation. Cancer Cell, 2010, 18, 122-134.	16.8	45
78	MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma. Head and Neck, 2016, 38, E189-97.	2.0	45
79	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports, 2017, 7, 43013.	3.3	44
80	Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence. Modern Pathology, 2017, 30, 1387-1401.	5.5	44
81	MicroRNA expression profiling of thymic epithelial tumors. Lung Cancer, 2014, 85, 197-204.	2.0	43
82	ÎEF1 repressor controls selectively p53 family members during differentiation. Oncogene, 2005, 24, 7273-7280.	5.9	42
83	Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. International Journal of Molecular Sciences, 2017, 18, 961.	4.1	41
84	Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget, 2015, 6, 5547-5566.	1.8	41
85	Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. Oncotarget, 2014, 5, 4129-4143.	1.8	40
86	Î²-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. Nature Communications, 2019, 10, 3196.	12.8	40
87	Targeting TEAD/YAP-transcription-dependent necrosis, TRIAD, ameliorates Huntingtonâ€™s disease pathology. Human Molecular Genetics, 2016, 25, ddw303.	2.9	38
88	Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages. Breast Cancer Research, 2018, 20, 59.	5.0	38
89	A Division of Labor between YAP and TAZ in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2020, 80, 4145-4157.	0.9	38
90	p73 Is Regulated by Phosphorylation at the G2/M Transition. Journal of Biological Chemistry, 2003, 278, 49196-49202.	3.4	37

#	Article	IF	Citations
91	p73-induced apoptosis: A question of compartments and cooperation. Biochemical and Biophysical Research Communications, 2005, 331, 688-693.	2.1	37
92	The locus of microRNA-10b. Cell Cycle, 2013, 12, 2371-2375.	2.6	37
93	Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73. Journal of Biological Chemistry, 2003, 278, 10546-10555.	3.4	36
94	ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters. OMICS A Journal of Integrative Biology, 2011, 15, 305-312.	2.0	36
95	VDR primary targets by genome-wide transcriptional profiling. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 348-356.	2.5	36
96	ID4: a new player in the cancer arena. Oncotarget, 2010, 1, 48-58.	1.8	36
97	Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion. Oncotarget, 2015, 6, 18134-18150.	1.8	36
98	A Role of p73 in Mitotic Exit. Journal of Biological Chemistry, 2005, 280, 30354-30360.	3.4	35
99	p73-Mediated Chemosensitivity: A Preferential Target of Oncogenic Mutant p53. Cell Cycle, 2003, 2, 345-346.	2.6	34
100	MicroRNAs as Key Effectors in the p53 Network. International Review of Cell and Molecular Biology, 2017, 333, 51-90.	3.2	34
101	Melatonin and Hippo Pathway: Is There Existing Cross-Talk?. International Journal of Molecular Sciences, 2017, 18, 1913.	4.1	34
102	Metformin, diet and breast cancer: An avenue for chemoprevention. Cell Cycle, 2009, 8, 2661-2661.	2.6	33
103	Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease. Seminars in Cell and Developmental Biology, 2020, 98, 105-117.	5.0	33
104	PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2956-2971.	7.0	33
105	Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells. Oncotarget, 2017, 8, 95674-95691.	1.8	33
106	MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration. Carcinogenesis, 2018, 39, 293-304.	2.8	32
107	Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. Breast Cancer Research, 2013, 15, R46.	5.0	31
108	MicroRNAs: short non-coding players in cancer chemoresistance. Molecular and Cellular Therapies, 2014, 2, 16.	0.2	31

#	Article	IF	Citations
109	The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas. Cancers, 2019, 11, 1347.	3.7	31
110	microRNA-378a-5p iS a novel positive regulator of melanoma progression. Oncogenesis, 2020, 9, 22.	4.9	30
111	MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study. Carcinogenesis, 2018, 39, 98-108.	2.8	29
112	<scp>AMPK</scp> Î²1 reduces tumor progression and improves survival in p53 null mice. Molecular Oncology, 2017, 11, 1143-1155.	4.6	28
113	Argonaute 2 drives miR-145-5p-dependent gene expression program in breast cancer cells. Cell Death and Disease, 2019, 10, 17.	6.3	28
114	microRNAs and cancer metabolism reprogramming: the paradigm of metformin. Annals of Translational Medicine, 2014, 2, 58.	1.7	28
115	Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells. Cell Cycle, 2012, 11, 132-140.	2.6	27
116	Direct and delayed Xâ€rayâ€induced DNA damage in male mouse germ cells. Environmental and Molecular Mutagenesis, 2012, 53, 429-439.	2.2	27
117	MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. Seminars in Cell and Developmental Biology, 2016, 50, 133-142.	5.0	27
118	Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation. Molecular Cancer, 2017, 16, 88.	19.2	27
119	LINC00174 is a novel prognostic factor in thymic epithelial tumors involved in cell migration and lipid metabolism. Cell Death and Disease, 2020, 11, 959.	6.3	27
120	Hippo andrassf1aPathways: A Growing Affair. Molecular Biology International, 2012, 2012, 1-12.	1.7	26
121	Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention. Metabolites, 2013, 3, 1051-1075.	2.9	26
122	MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer. Oncotarget, 2017, 8, 29540-29557.	1.8	26
123	Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. Cancer Biology and Therapy, 2016, 17, 79-82.	3.4	25
124	TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. Journal of Experimental and Clinical Cancer Research, 2020, 39, 200.	8.6	25
125	ID4: a new player in the cancer arena. Oncotarget, 2010, 1, 48-58.	1.8	25
126	Transcriptional Regulation by Mutant p53 and Oncogenesis. Sub-Cellular Biochemistry, 2014, 85, 91-103.	2.4	24

#	Article	IF	Citations
127	Downregulation of microRNAs 145-3p and 145-5p Is a Long-term Predictor of Postmenopausal Breast Cancer Risk: The ORDET Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2471-2481.	2.5	24
128	Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19479-19484.	7.1	23
129	Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1Î± stabilization. Journal of Experimental and Clinical Cancer Research, 2017, 36, 32.	8.6	23
130	Cheâ€1 is targeted by câ€Myc to sustain proliferation in preâ€Bâ€cell acute lymphoblastic leukemia. EMBO Reports, 2018, 19, .	4.5	23
131	YAP and endothelin-1 signaling: an emerging alliance in cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 27.	8.6	23
132	CircPVT1: a pivotal circular node intersecting Long Non-Coding-PVT1 and c-MYC oncogenic signals. Molecular Cancer, 2022, 21, 33.	19.2	23
133	Metformin: Metabolic Rewiring Faces Tumor Heterogeneity. Cells, 2020, 9, 2439.	4.1	22
134	Circular RNAs in Embryogenesis and Cell Differentiation With a Focus on Cancer Development. Frontiers in Cell and Developmental Biology, 2020, 8, 389.	3.7	22
135	The Cancer-associated K351N Mutation Affects the Ubiquitination and the Translocation to Mitochondria of p53 Protein. Journal of Biological Chemistry, 2011, 286, 39693-39702.	3.4	21
136	Cdx2 Polymorphism Affects the Activities of Vitamin D Receptor in Human Breast Cancer Cell Lines and Human Breast Carcinomas. PLoS ONE, 2015, 10, e0124894.	2.5	21
137	hMENA is a key regulator in endothelin-1/Î²-arrestin1â€“induced invadopodial function and metastatic process. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3132-3137.	7.1	21
138	METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors. Clinical Epigenetics, 2021, 13, 173.	4.1	21
139	Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nature Communications, 2022, 13, 2800.	12.8	21
140	Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Current Genomics, 2008, 9, 200-207.	1.6	20
141	Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines. Cancer Letters, 2018, 433, 18-32.	7.2	20
142	miR-181c associates with tumor relapse of high grade osteosarcoma. Oncotarget, 2015, 6, 13946-13961.	1.8	20
143	p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53. Cell Cycle, 2003, 2, 348-9.	2.6	20
144	Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. Cell Death and Differentiation, 2021, 28, 1493-1511.	11.2	19

#	Article	IF	Citations
145	SNPs in DNA repair or oxidative stress genes and late subcutaneous fibrosis in patients following single shot partial breast irradiation. Journal of Experimental and Clinical Cancer Research, 2012, 31, 7.	8.6	17
146	microRNAs: short non-coding bullets of gain of function mutant p53 proteins. Oncoscience, 2014, 1, 427-433.	2.2	17
147	Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle, 2009, 8, 3396-3405.	2.6	16
148	Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. Journal of Experimental and Clinical Cancer Research, 2009, 28, 135.	8.6	16
149	Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition. RNA Biology, 2015, 12, 690-700.	3.1	16
150	Interaction of mutant p53 with p73: A Surface Plasmon Resonance and Atomic Force Spectroscopy study. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 1958-1964.	2.4	15
151	Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia. Frontiers in Cell and Developmental Biology, 2020, 8, 257.	3.7	15
152	MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies. Translational Cancer Research, 2021, 10, 3090-3110.	1.0	15
153	YAP1 Meets Tumor Suppression. Molecular Cell, 2007, 27, 863-864.	9.7	14
154	p53: The pivot between cell cycle arrest and senescence. Cell Cycle, 2010, 9, 4266-4265.	2.6	14
155	Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. BMC Cancer, 2011, 11, 291.	2.6	14
156	PML Surfs into HIPPO Tumor Suppressor Pathway. Frontiers in Oncology, 2013, 3, 36.	2.8	14
157	The Hippo Tumor Suppressor Pathway: A Brainstorming WorkshopA report on the research meeting â€œThe Hippo Tumor Suppressor Pathway: A Brainstorming Workshopâ€•sponsored mainly by the Regina Elena Cancer Center and the Nicola Foundation and held in Rome, Italy, on 22 and 23 April 2009.. Science Signaling, 2009, 2, mr6.	3.6	13
158	Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 349.	8.6	13
159	Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer. Communications Biology, 2020, 3, 677.	4.4	13
160	Id2gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle, 2010, 9, 2464-2466.	2.6	12
161	Editorial: (Thematic Issue: MicroRNAs: Non Coding Pleiotropic Factors in Development, Cancer) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.2	12
162	Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. Cancer Letters, 2020, 492, 84-95.	7.2	12

#	Article	IF	Citations
163	H-Ras gene takes part to the host immune response to COVID-19. Cell Death Discovery, 2021, 7, 158.	4.7	11
164	Allelic Expression Imbalance ofTP53Mutated and Polymorphic Alleles in Head and Neck Tumors. OMICS A Journal of Integrative Biology, 2011, 15, 375-381.	2.0	10
165	Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. Blood Advances, 2020, 4, 5616-5630.	5.2	10
166	Paracrine Signaling from Breast Cancer Cells Causes Activation of ID4 Expression in Tumor-Associated Macrophages. Cells, 2020, 9, 418.	4.1	10
167	Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both?. Aging, 2016, 8, 1153-1155.	3.1	10
168	Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 344.	8.6	9
169	YAP and TAZ: Monocorial and bicorial transcriptional co-activators in human cancers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188756.	7.4	9
170	BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer. Communications Biology, 2020, 3, 546.	4.4	8
171	Cancer at the time of the COVID-19 hurricane. Journal of Experimental and Clinical Cancer Research, 2020, 39, 74.	8.6	8
172	MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. Communications Biology, 2022, 5, .	4.4	8
173	PGC1Î± Confers Specificityâ€"Metabolic Stress and p53-Dependent Transcription. Molecular Cell, 2011, 44, 515-516.	9.7	7
174	Gender, mutant p53 and PML: A growing â€œaffaireâ€•in tumor suppression and oncogenesis. Cell Cycle, 2013, 12, 1824-1825.	2.6	7
175	Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes a Prognostic Signature. International Journal of Molecular Sciences, 2021, 22, 12071.	4.1	7
176	p63 regulation by microRNAs. Cell Cycle, 2009, 8, 1466-1470.	2.6	6
177	Omics Underpins Novel Clues on VDR Chemoprevention Target in Breast Cancer. OMICS A Journal of Integrative Biology, 2011, 15, 337-346.	2.0	6
178	Radioresistance in Head and Neck Squamous Cell Carcinoma â€" Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies. , 2015, , .		6
179	Evidence of a SARS-CoV-2 double Spike mutation D614G/S939F potentially affecting immune response of infected subjects. Computational and Structural Biotechnology Journal, 2022, 20, 733-744.	4.1	6
180	Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. Oncogene, 1997, 15, 607-611.	5.9	5

#	Article	IF	Citations
181	Molecular Genetics and Biology of Head and Neck Squamous Cell Carcinoma: Implications for Diagnosis, Prognosis and Treatment. , 2012, , .		5
182	MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. Cell Cycle, 2013, 12, 1823-1823.	2.6	5
183	Drugging the Master Regulator TP53 in Cancer: Mission Possible?. Journal of Clinical Oncology, 2021, 39, 1595-1597.	1.6	5
184	Monoclonal antibodies raised against Xenopus p53 interact with human p73. Oncogene, 2002, 21, 1304-1308.	5.9	4
185	ChIP-on-chip to Identify Mutant p53 Targets. Methods in Molecular Biology, 2013, 962, 211-226.	0.9	4
186	Use of Buffy Coat miRNA Profiling for Breast Cancer Prediction in Healthy Women. Methods in Molecular Biology, 2016, 1379, 13-19.	0.9	4
187	Zebrafish as experimental model to establish the contribution of mutant p53 and ID4 to breast cancer angiogenesis in vivo. Journal of Thoracic Disease, 2018, 10, E231-E233.	1.4	4
188	What biomarkers (if any) for precise medicine?. Aging, 2015, 7, 533-534.	3.1	4
189	The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. Molecular Cell, 2005, 19, 429.	9.7	3
190	P73, P63 and Mutant P53: Members of Protein Complexs Floating in Cancer Cells. , 2007, , 223-232.		3
191	YAP and p73: A Matter of Mutual Specificity in Tumor Suppression. , 2013, , 147-172.		3
192	Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins. Frontiers in Oncology, 2016, 6, 170.	2.8	3
193	Arenavirus as a potential etiological agent of odontogenic tumours in humans. Journal of Experimental and Clinical Cancer Research, 2020, 39, 34.	8.6	3
194	Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. Cell Death and Disease, 2021, 12, 1019.	6.3	3
195	Novel insights into the cytoplasmic functions of p53. Cell Cycle, 2010, 9, 2491-2501.	2.6	1
196	In vivo experimental models account for higher complexity than in vitro preclinical settings in cancer. Journal of Thoracic Disease, 2019, 11, S461-S464.	1.4	1
197	Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research Purposes. Frontiers in Oncology, 2020, 10, 922.	2.8	1
198	Two distinct TP53 mutations in HNSCC primary tumor: Only one circulates in the blood. Oral Oncology, 2021, 115, 105096.	1.5	1

#	Article	IF	Citations
199	Long Non-Coding RNAs in the Cell Fate Determination of Neoplastic Thymic Epithelial Cells. Frontiers in Immunology, 2022, 13, 867181.	4.8	1
200	Mitosis poisons p53. Cell Cycle, 2008, 7, 3287-3291.	2.6	0
201	Tetraploidy triggers mithocondria. Cell Cycle, 2009, 8, 1305-1307.	2.6	0
202	Stability strengths oncogenic activity. Cell Cycle, 2010, 9, 1456-1465.	2.6	0
203	Tumor suppression. FEBS Letters, 2014, 588, 2557-2557.	2.8	0
204	Genomic Instability: The Pivotal Role of Mutant P53 in Human Cancers. Chemotherapy, 2016, 05, .	0.0	0
205	microRNAs in Cancer Chemoprevention: Method to Isolate Them from Fresh Tissues. Methods in Molecular Biology, 2016, 1379, 21-29.	0.9	0
206	<scp>cTAZ</scp> : a safeguard factor of antiviral response. EMBO Reports, 2019, 20, .	4.5	0
207	Gain of Function p53. , 2011, , 1486-1489.		0
208	Inhibitor of DNA Binding 4 (ID4). , 2016, , 1-7.		0
209	Gain-of-Function p53. , 2016, , 1828-1831.		0
210	Inhibitor of DNA Binding 4 (ID4). , 2018, , 2593-2600.		0
211	Circular RNA YAP1: a new player in gastric cancer. Translational Cancer Research, 2019, 8, S195-S197.	1.0	0
212	p73, p63 and Mutant p53: Members of Protein Complexes Floating in Cancer Cells. , 2007, , 223-232.		0